CARLSBAD, Calif., Sept. 05, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced its participation in the upcoming...
Dror Ortho-Design (DROR) Spotlight Series
In this episode, we are featuring Dror Ortho-Design, Inc. (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a single custom-made smart...
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
NEW YORK - Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Therapeutic...
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual...
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
CARMEL, Ind., Aug. 27, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical...
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
NEW YORK - Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by independent...
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
NEW YORK - Delcath Systems, Inc. (Nasdaq: DCTH) ("Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by investigators at the...
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
PONTE VEDRA, Fla., Aug. 22, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
Aurora Spine Corporation Announces Second Quarter 2024 Financial Results
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., Aug. 21, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves...
Published Findings Highlight Tecarfarin’s Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Analysis features the growing need to evolve anticoagulation therapy beyond warfarin to avoid gastrointestinal bleeding, a significant and common complication for left ventricular assist device (LVAD) patients resulting in expensive hospitalizations Tecarfarin, a...
Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress
NEW YORK - Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it will present data from its FOCUS Phase 3 study at the 2024...
INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment and acquisition of fertility clinics,...
Cadrenal Therapeutics to Present at Upcoming Investor Conferences
PONTE VEDRA, Fla., Aug. 14, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
Precision Optics Announces Pricing of $1.4 Million Registered Direct Offering of Common Stock
GARDNER, Mass., Aug. 14, 2024 -- Precision Optics Corporation, Inc. (NASDAQ: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that it has entered into securities purchase...
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint development agreement with a Top 10 global dairy company for the...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024
PORTLAND, Maine, Aug. 13, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
CARMEL, Ind., Aug. 13, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical...
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted one equity award, previously approved...
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2024 on...
NeurAxis Reports Second Quarter 2024 Financial Results
Conference call will be held today, Friday, August 9 at 9:00 am ETCarmel, Ind., Aug. 09, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating...
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
DENVER, CO / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted...
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
PONTE VEDRA, Fla., Aug. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
Conference Call Scheduled for Wednesday, August 14, 2024 at 9:00 AM ETPORTLAND, Maine, Aug. 07, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and...
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
PONTE VEDRA, Fla., Aug. 6, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx SegmentEliminates Materially All Remaining Expenses Associated with the Consumer Health BusinessProvides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / August 6,...
Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
Company Reports $7.8 million in Quarterly Revenue Conference Call Today at 4:30pm Eastern Time QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic...
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024
CARMEL, Ind., Aug. 05, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized...
Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced today that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-on...
Dror Ortho-Design, Inc. Launches ZSMILE User Experience Trial
JERUSALEM, Aug. 05, 2024 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a...
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
Reports record revenue of $17.9 million for the second quarter of 2024, an increase of 11.2 percent over the comparable period 2023.Reports GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42 for the second quarter of 2024.Reports second quarter of 2024...
Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and...
Delcath Systems to Participate in Upcoming Investor Conferences
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences: BTIG...
IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
Winter Springs, Fla., July 25, 2024 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the...
Delcath Systems to Host Second Quarter 2024 Earnings Call
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss...
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
PONTE VEDRA, Fla., July 17, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
Dror Ortho-Design, Inc. Launches New ZSMILE Product Brand
JERUSALEM, July 17, 2024 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a...
Aurora Spine Corporation to Attend Sixth Annual American Society of Pain & Neuroscience Conference
CARLSBAD, Calif., July 10, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it will be participating in the...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
PORTLAND, Maine, July 09, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing
GARDNER, Mass., July 08, 2024 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice...
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of...
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debtInterest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life...
Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
PONTE VEDRA, Fla., June 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
CARMEL, Ind., June 07, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced a...
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market
Trading to commence effective on the market open June 14, 2024WINTER SPRINGS, Fla., June 07, 2024 -- IRADIMED CORPORATION ("Iradimed") (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its...
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®
PORTLAND, Maine , June 05, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
PORTLAND, Maine, June 04, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has the potential to improve the time in therapeutic range a factor...
Beyond Air (XAIR) Company Webcast
In this presentation, we welcome Beyond Air, Nasdaq ticker symbol XAIR. And with us today is their CEO and Chairman, Steve Lisi. Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and...
Dyadic to Attend Industry Events in June
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well...
Modular Medical (MODD) Fireside Chat
In this presentation, we welcome Modular Medical, NASDAQ ticker symbol MODD. And with us today is their CEO, Jeb Besser. Modular Medical's mission is the commercialization of an innovative insulin pump using modernized technology to increase pump adoption in the...
